RNA editing startup Tacit Therapeutics launches with $19M for brain diseasesnews2026-03-09T13:00:55+00:00March 9th, 2026|Endpoints News|
GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfrontnews2026-03-09T10:29:43+00:00March 9th, 2026|Endpoints News|
Roche’s big-hope breast cancer drug fails in crucial first-line trialnews2026-03-09T08:26:14+00:00March 9th, 2026|Endpoints News|
UniQure’s dispute with FDA; Zealand’s obesity readout; China takes on world’s most expensive medicines; and more news2026-03-07T11:00:32+00:00March 7th, 2026|Endpoints News|
Vinay Prasad to exit FDA again, following latest round of controversynews2026-03-06T22:16:03+00:00March 6th, 2026|Endpoints News|
Lonza sells capsule and health ingredients unit for $2.2Bnews2026-03-06T19:50:51+00:00March 6th, 2026|Endpoints News|
Servier to buy Day One for $2.5B, gaining rare oncology medicinesnews2026-03-06T15:54:59+00:00March 6th, 2026|Endpoints News|
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus datanews2026-03-06T15:35:55+00:00March 6th, 2026|Endpoints News|
Post-Hoc Live: What will the US government do about China biotech?news2026-03-06T13:35:00+00:00March 6th, 2026|Endpoints News|
Pfizer gets obesity drug approval in China shortly after buying local rightsnews2026-03-06T12:29:57+00:00March 6th, 2026|Endpoints News|
